An Italian firm has published promising results from its phase-two clinical trials, in which its Covid-19 vaccine induced an antibody response in 93% of volunteers three weeks after the first dose, reaching 99% after the second.
In a press statement on Monday, Italian biotech company ReiThera said its candidate vaccine was well tolerated and “induces clear immune responses in trial subjects.”
Continue reading https://on.rt.com/bc6e